Compare Haemonetics Corp. with Similar Stocks
Dashboard
1
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 8.96
2
Poor long term growth as Net Sales has grown by an annual rate of 7.32% and Operating profit at 8.03% over the last 5 years
3
Flat results in Jun 25
4
With ROCE of 12.30%, it has a attractive valuation with a 2.47 Enterprise value to Capital Employed
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
USD 2,774 Million (Small Cap)
16.00
NA
0.00%
0.95
19.13%
3.04
Revenue and Profits:
Net Sales:
346 Million
(Quarterly Results - Mar 2026)
Net Profit:
-20 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.11%
0%
-7.11%
6 Months
-19.37%
0%
-19.37%
1 Year
-18.95%
0%
-18.95%
2 Years
-40.89%
0%
-40.89%
3 Years
-32.63%
0%
-32.63%
4 Years
6.25%
0%
6.25%
5 Years
-9.7%
0%
-9.7%
Haemonetics Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.32%
EBIT Growth (5y)
15.08%
EBIT to Interest (avg)
8.96
Debt to EBITDA (avg)
2.49
Net Debt to Equity (avg)
1.13
Sales to Capital Employed (avg)
0.67
Tax Ratio
20.93%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
10.56%
ROE (avg)
14.77%
Valuation key factors
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
3.04
EV to EBIT
14.93
EV to EBITDA
10.21
EV to Capital Employed
2.05
EV to Sales
2.76
PEG Ratio
0.57
Dividend Yield
NA
ROCE (Latest)
13.73%
ROE (Latest)
19.13%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 106 Schemes (55.91%)
Foreign Institutions
Held by 149 Foreign Institutions (14.86%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
346.40
339.00
2.18%
Operating Profit (PBDIT) excl Other Income
51.40
96.90
-46.96%
Interest
5.40
8.10
-33.33%
Exceptional Items
-74.50
-1.50
-4,866.67%
Consolidate Net Profit
-20.10
44.70
-144.97%
Operating Profit Margin (Excl OI)
148.50%
205.20%
-5.67%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 2.18% vs 3.57% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -144.97% vs 15.50% in Dec 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
1,334.00
1,360.80
-1.97%
Operating Profit (PBDIT) excl Other Income
397.10
337.90
17.52%
Interest
28.70
9.90
189.90%
Exceptional Items
-84.70
-2.10
-3,933.33%
Consolidate Net Profit
97.30
167.70
-41.98%
Operating Profit Margin (Excl OI)
181.00%
163.40%
1.76%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is -1.97% vs 3.95% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is -41.98% vs 42.60% in Mar 2025
About Haemonetics Corp. 
Haemonetics Corp.
Pharmaceuticals & Biotechnology
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company's segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.
Company Coordinates 
Company Details
125 SUMMER STREET , BOSTON MA : 02110
Registrar Details






